Abbott Laboratories (LON:0Q15)
United Kingdom · Delayed Price · Currency is GBP · Price in USD | Market Cap | 129.85B -22.3% |
| Revenue (ttm) | 36.33B +10.0% |
| Net Income | 3.52B -66.4% |
| EPS | 2.01 -66.2% |
| Shares Out | n/a |
| PE Ratio | 36.45 |
| Forward PE | 16.87 |
| Dividend | 1.90 (2.59%) |
| Ex-Dividend Date | Oct 15, 2026 |
| Volume | 21,701 |
| Open | 102.30 |
| Previous Close | 102.82 |
| Day's Range | 97.54 - 106.38 |
| 52-Week Range | 82.05 - 132.00 |
| Beta | 0.58 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 21, 2026 |
About Abbott Laboratories
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, h... [Read more]
Financial Performance
In 2025, Abbott Laboratories's revenue was $44.33 billion, an increase of 5.67% compared to the previous year's $41.95 billion. Earnings were $6.50 billion, a decrease of -51.49%.
Financial numbers in USD Financial StatementsNews
Abbott Laboratories Stock (ABT) Dips 2% on Spinoff Plans for Abbott Nutrition
Abbott Laboratories stock was down over 2% on plans to spinoff its nutrition business into a separate public company.
Abbott expects both companies to pay a dividend once separation complete
Expects combined dividend to be paid by Abbott (ABT) and new Nutrition company to be equal to Abbott’s dividend at time of separation. Expects Nutrition spin-off to be a market…
Abbott Laboratories Earnings Call Transcript: Q3 2026
Q3 sales rose 7% and adjusted EPS was $1.42, with growth accelerating. Plans call for a tax-free nutrition separation by end-2027; near-term outlook reflects EP and diabetes headwinds, while 2027 growth acceleration is expected.
Abbott Laboratories Earnings release: Q3 2026
Abbott Laboratories released its Q3 2026 earnings on October 21, 2026, summarizing the period's financial results.
Abbott Laboratories Stock (ABT) Plunges 4% as It Separates $8.5B Nutrition Business
Shares in Abbott Laboratories ($ABT) were down 4% in pre-market trading today as it announced that it planned to separate its global Nutrition business into an independent publicly traded company…
Abbott to Carve Out Nutrition Business Into Independent Company
Abbott plans to separate its nutrition business into an independent company with about $8.5 billion in annual sales.
Abbott reports Q3 adjusted EPS $1.42, consensus $1.41
Reports Q3 revenue $13.01B, consensus $12.99B. “Abbott (ABT) delivered strong third-quarter results, reflecting balanced growth across our portfolio,” said Robert B. Ford, chairman and chief executive...
Abbott sees Q4 adjusted EPS $1.62-$1.67, consensus $1.64
07:31 EDT Abbott (ABT) sees Q4 adjusted EPS $1.62-$1.67, consensus $1.64
Abbott lowers 2026 sales growth forecast on medical device weakness
Abbott said it plans to separate its nutrition business into an independent, publicly traded company and reduced its 2026 sales growth forecast, sending shares down 3.4% in premarket trading.
Abbott to separate global Nutrition business into independent company
07:25 EDT Abbott (ABT) to separate global Nutrition business into independent company
Abbott to separate global Nutrition business into independent public company
Abbott (ABT) announced its intention to separate its Nutrition business into an independent, publicly traded company that will be a global leader in the rapidly expanding healthy nutrition market with...
Abbott Reports Third-Quarter 2026 Results and Reaffirms Full-Year EPS Guidance
Third-quarter reported sales growth of 14.5 percent; comparable sales growth of 7.0 percent Third-quarter GAAP diluted EPS of $0.53; adjusted diluted EPS of $1.42 Expands portfolio with key new produc...
Abbott announces its intention to separate its global Nutrition business into an independent, publicly traded company
Separation will unlock potential of both companies to pursue distinct growth and value-creation strategies The new Nutrition company will be a global leader in the rapidly growing healthy nutrition ma...
Abbott introduces Ensure® Max Protein 3-in-1 Muscle Support, bringing the benefits of a supplement stack into one scoop
New powder combines 30 grams of high‑quality protein to help build muscle tissue,† 5 grams of creatine monohydrate to support muscle recovery‡* and 3 grams of calcium HMB (beta-hydroxy-beta-methylbuty...
Abbott receives FDA approval for new CardioMEMS HF System capabilities that help patients engage in the care of their heart condition
For the first time, U.S. CardioMEMS patients will be able to view pulmonary artery pressure (PAP) readings and receive personalized medication updates through the CardioGuide HF App Rising PAP can sig...
Abbott hosts conference call for third-quarter earnings
ABBOTT PARK, Ill., Sept. 30, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its third-quarter 2026 financial results on Wednesday, Oct. 21, before the market opens.
Abbott launches SimpleScreen™ CRC blood test, joining Cologuard Plus® in its colorectal cancer screening portfolio
Only Abbott offers a complete screening solution combining end-to-end support with both stool- and blood-based colorectal cancer screening options, giving healthcare providers more ways to help eligib...
Abbott And Berry Street Partner To Expand Personalized Nutrition Support For Consumers Seeking Better Metabolic Health
Partnership combines Abbott's Lingo continuous glucose monitor with Berry Street's insurance-covered registered dietitian support, helping consumers translate glucose insights into healthier behaviors...
Abbott declares 411th consecutive quarterly dividend
ABBOTT PARK, Ill., Sept. 17, 2026 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 63 cents per share.
Abbott to pay $384 mln over contaminated infant formula allegations, US Justice Dept says
Abbott Laboratories has agreed to pay more than $384 million to settle allegations related to contaminated infant formula, the U.S. Justice Department said on Monday.
Abbott reaches agreement with Department of Justice to resolve claims relating to 2022 infant formula recall
Settlement does not represent any finding of fault or liability As the government has previously indicated, it has closed its criminal investigation on this matter Tests by government regulators of un...
Abbott receives FDA approval for its TactiFlex™ Duo Ablation Catheter to treat people with abnormal heart rhythms
Abbott's TactiFlex™ Duo Ablation Catheter, Sensor Enabled™ combines pulsed field ablation (PFA) and radiofrequency (RF) energy in a single catheter to treat complex atrial fibrillation (AFib) cases St...
Abbott launches the first and only ready-to-feed liquid infant formula made with whole milk in the U.S. at similar price to its existing Similac powdered formula
New Similac 360 Total Care Made With Whole Milk combines creamy whole milk for a fat blend that more closely resembles the fats in breast milk and five immune-nourishing prebiotics to help support bab...